Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Spiriva HandiHaler (tiotropium bromide inhalation powder)


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

Sections Modified

ADVERSE REACTIONS

  • ...The following adverse reactions have been identified during worldwide post-approval use of Spiriva HandiHaler:
    • application site irritation (glossitis, mouth ulceration, and pharyngolarygeal pain)

PATIENT PACKAGE INSERT

  • The following statement was added on page 1, under drug name:
    • Do Not Swallow Capsules.
      For Use With HandiHaler Only.
  • Removing a Spiriva Capsule (Figure 4):
    • Do not swallow Spiriva Capsules.

 

Label approved 06/20/2008 is not available on Drugs@FDA 

 

-
-